Expanded Access for Anti-IL8

Bristol-Myers Squibb (BMS)

Status

Treatments: Biological: Anti-IL8

Study type: Expanded Access

Funder types: Industry

Identifiers

NCT05210894

CA027-014

Details and patient eligibility

About

This is an expanded access designed to provide access to Anti-IL8 for eligible participants.

Sex

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria